SavedAdd your journal

Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 2

Non-Nutritional Medical Treatments in Dry-Form (Non-Neovascular) Age Related Macular Degeneration

Kuru Tip (Non-Neovasküler) Yaşa Bağlı Maküla Dejenerasyonunda Nutrisyon Dışı Medikal Tedaviler

METE GÜLER
Fatih Cem GÜL
Murat KAYA
Pages
145–148
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review it is aimed to discuss recent non-nutritional treatments for dry AMD and geographic atrophy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age related macular degeneration (AMD) is the major cause of blindness for the elderly population in the developed world.
📊
Key Findings & Data:The Age-Related Eye Disease Study (AREDS) demonstrated protective effect of dietary supplementation of antioxidants to slow down the progression of dry AMD.
💡
Conclusion & Impact:In this review it is aimed to discuss recent non-nutritional treatments for dry AMD and geographic atrophy
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Age related macular degeneration (AMD) is the major cause of blindness for the elderly population in the developed world. Although vision loss is mainly due to the neovascular form, dry AMD remains a challenge for ophthalmologists because of the lack of effective therapies. The Age-Related Eye Disease Study (AREDS) demonstrated protective effect of dietary supplementation of antioxidants to slow down the progression of dry AMD. On the other hand, there has been no proven drug treatment for dry AMD to date. In this review it is aimed to discuss recent non-nutritional treatments for dry AMD and geographic atrophy

Özet

Yaşa bağlı maküla dejenerasyonu (YBMD) gelişmiş ülkelerdeki yaşlı nüfusta en önemli körlük nedenidir. Görme kaybı esas olarak yaş tip ile olsa da etkili bir tedavisinin bulunmayışı nedeniyle kuru tip YBMD oftalmologlar için halen önemli bir sorundur. Age-Related Eye Disease Study (AREDS) çalışması diyetle antioksidanların alınmasının kuru tip YBMD' nin ilerleyişini yavaşlattığını göstermiştir. Öte yandan günümüzde kuru tip YBMD'nin tedavisinde kanıtlanmış bir ilaç tedavisi bulunmamaktadır. Bu derlemede kuru tip YBMD ve coğrafik atrofi için güncel nutrisyon dışı tedavilerin tartışılması amaçlanmaktadır

🔖

Cite This Article

GÜLER, M., GÜL, F. C., KAYA, M. (2017). Non-Nutritional Medical Treatments in Dry-Form (Non-Neovascular) Age Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 2, 145–148. https://ajindex.com/articles/197474

References (7)

  1. Friedman DS, O’Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004
  2. 122(4):564- 572. 2-Zając-Pytrus HM, Pilecka A, Turno-Kręcicka A, Adamiec-Mroczek J, Misiuk-Hojło M. The Dry Form of Age-Related Macular Degeneration (AMD): The Current Concepts of Pathogenesis and Prospects for Treatment. Adv Clin Exp Med. 2015
  3. 24(6):1099-1104. 3-Hanus J, Zhao F, Wang S. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016
  4. 100(1):122-127 4-Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No 8. Arch Ophthalmol 2001
  5. 1417–1436. 5-Age-Related Eye Disease Study 2 Research Group: Lutein+ Zeaxanthin and Omega-3 Fatty Acids for Age- Related Macular Degeneration: The Age-Related Eye Disease 2 (AREDS) Randomized Clinical Trial. JAMA 2013, 309:2005-15. 6- Le KN, Gibiansky L, van Lookeren Campagne M, Good J, Davancaze T, Loyet KM, et al. Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy. CPT Pharmacometrics Syst Pharmacol. 2015
  6. 4(10):595-604. 7- Özkan HH, Çıtırık M, Teke MY. Kuru Tip Yaşa Bağlı Maküla Dejenerasyonu Tedavisinde Lampalizumab. http://www.ulucanlarretina.com/ Son Güncellenme Tarihi 01/06/2016). 8- Rohrer B, Guo Y, Kunchithapautham K, Gilkeson GS. Eliminat¬ing complement factor D reduces photoreceptor susceptibility to light-induced damage. Invest Ophthalmol Vis Sci. 2007
  7. 48(11):5282-5289 9-ClinicalTrials.gov. A study investigating the efficacy and safety of lampalizumab intravitreal injections in participants with geographic atrophy secondary to age-related macular degeneration (CHROMA). https://clinicaltrials. gov/ct2/show/NCT02247479. erişim tarihi 05.01.2017 10-ClinicalTrials.gov. A study investigating the efficacy and safety of lampalizumab intravitreal injections in participants with geographic atrophy secondary to age-related macular degeneration (SPECTRI). https://clinicaltrials.gov/ ct2/show/NCT02247531.erişim tarihi 05.01.2017 11-Yehoshua Z, de Amorim Garcia Filho CA, Nunes RP, Gregori G, Penha FM, Moshfeghi AA, et al. Systemic complement inhibition with eculizumab for geographic atrophy in age-related macul